Nor-binaltorphimine precipitates withdrawal and excitatory amino acid release in the locus ceruleus of butorphanol - But not morphine-dependent rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 2, 1997, Pages 932-938

  Feng, Yangzheng ^a   Rockhold, Robin W ^a   Ho, Ing K ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; BUTORPHANOL; EXCITATORY AMINO ACID; GLUTAMIC ACID; KAPPA OPIATE RECEPTOR; MORPHINE; NORBINALTORPHIMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DEPENDENCE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LOCUS CERULEUS; MALE; MICRODIALYSIS; MORPHINE ADDICTION; NONHUMAN; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

ANIMALS; BUTORPHANOL; EXCITATORY AMINO ACIDS; LOCUS COERULEUS; MALE; MICRODIALYSIS; MORPHINE DEPENDENCE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0030831773     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. ABDELHAMID, E. E., SULTANA, M., PORTOGHESE, P. S. AND TAKEMORI, A. E.: Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 258: 299-303, 1991.
2. AGHAJANIAN, G. K.: Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature 276: 186-188, 1978.
3. AGHAJANIAN, G. K., KOGAN, J. H. AND MOGHADDAM, B.: Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: An in vivo microdialysis study. Brain Res. 636: 126-130, 1994.
4. AKAOKA, H. AND ASTON-JONES, G.: Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input. J. Neurosci. 11: 3830-3839, 1991.
5. ASTON-JONES, G., ENNIS, M., PIERIBONE, V. A., NICKELL, W. T. AND SHIPLEY, M. T.: The brain nucleus locus coeruleus: Restricted afferent control of a broad efferent network. Science 234: 734-737, 1986.
6. BROWN, G. R.: Stadol dependence: Another case. JAMA 254: 910, 1985.
7. CHANG, K. J., WEI, E. T., KILLIAN, A. AND CHANG, J. K.: Potent morphiceptin analogs: Structure activity relationships and morphine-like activities. J. Pharmacol. Exp. Ther. 227: 403-408, 1983.
8. DOBKIN, A. B., ARANDIA, H. Y., BYLES, P. H., AFRICA, B. F., CARUSO, F. S. AND NOVECK, R. J.: Butorphanol tartrate: 2. Safety and efficacy in balanced anesthesia. Can. Anesth. Soc. J. 23: 601-608, 1976.
9. ELLISON, D. W., BEAL, M. F. AND MARTIN, J. B.: Amino acid neurotransmitters in postmortem human brain analyzed by high performance liquid chromatography with electrochemical detection. J. Neurosci. Methods 19: 305-315, 1987.
10. ENNIS, M. AND ASTON-JONES, G.: A potent excitatory input to the nucleus locus coeruleus from the ventrolateral medulla. Neurosci. Lett. 71: 299-305, 1986.
11. ENNIS, M. AND ASTON-JONES, G.: Activation of locus coeruleus from nucleus paragigantocellularis: A new excitatory amino acid pathway in brain. J. Neurosci. 8: 3644-3657, 1988.
12. ENNIS, M., ASTON-JONES, G. AND SHIEKHATTAR, R.: Activation of locus coeruleus neurons by nucleus paragigantocellularis or noxious sensory stimulation is mediated by intracoerulear excitatory amino acid neurotransmission. Brain Res. 598: 185-195, 1992.
13. EVANS, W. S., BOWEN, J. N., GIORDANO, F. L. AND CLARK, B.: A case of Stadol dependence. JAMA 253: 2191-2192, 1985.
14. FENG, Y. Z., NARITA, M., TSENG, Y. T., HOSKINS, B. AND Ho, I. K.: Cross-tolerance between butorphanol and morphine in rats. Pharmacol. Biochem. Behav. 49: 657-661, 1994a.
15. FENG, Y. Z., TSENG, Y. T., JAW, S. P., HOSKINS, B. AND HO, I. K.: Tolerance development to butorphanol: Comparison with morphine. Pharmacol. Biochem. Behav. 49: 649-655, 1994b.
16. FENG, Y. Z., ZHANG, T., ROCKHOLD, R. W. AND HO, I. K.: Opioid receptor subtypes modulate pontine excitatory amino acid (EAA) levels differently in butorphanol and morphine dependence (Abstract). Soc. Neurosci. Abstr. 20: 1232, 1994c.
17. FENG, Y. Z., ZHANG, T., ROCKHOLD, R. W. AND HO, I. K.: Increased locus coeruleus glutamate levels are associated with naloxone-precipitated withdrawal from butorphanol in the rat. Neurochem. Res. 20: 745-751, 1995.
18. FENG, Y. Z., ZHANG, T., TOKUYAMA, S., ZHU, H., ROCKHOLD, R. W. AND HO, I. K.: μ-and δ-Opioid receptor antagonists precipitate similar withdrawal phenomena in butorphanol and morphine dependence. Neurochem. Res. 21: 63-71, 1996.
19. GOLD, M. S., POTTASH, A. C., SWEENEY, D. R. AND KLEBER, H. D.: Opiate withdrawal using clonidine. JAMA 243: 343-346, 1980.
20. 2 (CTOP) in mice. Eur. J. Pharmacol. 150: 355-360, 1988.
21. HOOVER, R. C. AND WILLIAMS, R. B.: Survey of butorphanol and nalbuphine diversion in U.S. hospitals. Am. J. Hosp. Pharm. 42: 1111-1113, 1985.
22. HORAN, P. AND HO, I. K.: Butorphanol precipitates abstinence in morphine-dependent rats. Eur. J. Pharmacol. 170: 265-268, 1989a.
23. HORAN, P. AND HO, I. K.: Comparative pharmacological and biochemical studies between butorphanol and morphine. Pharmacol. Biochem. Behav. 34: 847-854, 1989b.
24. HORAN, P. AND HO, I. K.: The physical dependence liability of butorphanol: A comparative study with morphine. Eur. J. Pharmacol. 203: 387-391, 1991.
25. HOSHI, K., MA, T. AND HO, I. K.: Precipitated κ-opioid agonist withdrawal increases glutamate in rat locus coeruleus. Eur. J. Pharmacol. 314: 301-306, 1996.
26. JASINSKI, D. R., PRESTON, K. L. AND TESTA, M.: Abuse potential evaluation of transnasally given butorphanol in humans (Abstract). Pharmacologist 30: A196, 1988.
27. JASINSKI, D. R., PVENICK, J. S., GRIFFITH, J. D., GORODETZKY, C. W. AND CONE, E. J.: Progress report from the Clinical Pharmacology Section of the Addiction Research Center, Committee on Problems of Drug Dependence (Abstract). Proc. Natl. Acad. Sci. USA 112: 120, 1976.
28. JAW, S. P., MAKIMURA, M., HOSKINS, B. AND HO, I. K.: Effects of norbinaltorphimine on butorphanol dependence. Eur. J. Pharmacol. 239: 133-140, 1993.
29. JAW, S. P., MAKIMURA, M., OH, K. W., HOSKINS, B. AND HO, I. K.: Involvement of κ-opioid receptors in opioid dependence/withdrawal: Studies using butorphanol. Eur. J. Pharmacol. 257: 153-160, 1994.
30. 3H]U-69 593: A highly selective ligand for the opioid κ receptor. Eur. J. Pharmacol. 109: 281-284, 1985.
31. LEANDER, J. D.: A kappa opioid effect: Increased urination in the rat. J. Pharmacol. Exp. Ther. 224: 89-94, 1983a.
32. LEANDER, J. D.: Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a κ-opioid receptor. Eur. J. Pharmacol. 86: 467-470, 1983b.
33. LIU, N., ROCKHOLD, R. W. AND HO, I. K.: Induced stereotyped behaviors in rats by electric stimulation of nucleus paragigantocellularis (Abstract). Pharmacologist 39: A108, 1997.
34. MALDONADO, R., STINUS, L., GOLD, L. H. AND KOOB, G. R.: Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261: 660-667, 1992.
35. MARTIN, W. R., EADES, C. G., THOMPSON, J. A., HUPPLER, R. E. AND GILBERT, P. E.: The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197: 517-532, 1976.
36. MCFADZEAN, I., LACEY, M. G., HILL, R. G. AND HENDERSON, G.: Kappa opioid receptor activation depresses excitatory synaptic input to rat locus coeruleus neurons in vitro. Neuroscience 20: 231-239, 1987.
37. MIYAMOTO, Y., PORTOGHESE, P. S. AND TAKEMORI, A. E.: Involvement of delta-2 opioid receptors in the development of morphine dependence in mice. J. Pharmacol. Exp. Ther. 264: 1141-1145, 1993.
38. OH, K. W., MAKIMURA, M., JAW, S. P., HOSKINS, B. AND HO, I. K.: Effects of β-funaltrexamine on butorphanol dependence. Pharmacol. Biochem. Behav. 42: 29-34, 1992.
39. PATTERSON, S. J., ROBSON, L. E. AND KOSTERLITZ, H. W.: Opioid Receptors. In The Peptides, Vol. 6, ed. by J. Meinhofer and E. Gross, pp. 147-189, Academic Press, New York, 1984.
40. PAXINOS, G. AND WATSON, C.: The Rat Brain in Stereotaxic Coordinates, 2nd ed., Academic Press, New York, 1986.
41. PICKER, M. J. AND DYKSTRA, L. A.: Discriminative stimulus effects of mu and kappa opioids in the pigeon: Analysis of the effects of full and partial mu and kappa agonists. J. Pharmacol. Exp. Ther. 249: 557-566, 1989.
42. PIRCIO, A. W., CYLYS, J. A., CAVANAGH, R. L., BUYNISKI, J. P. AND BIERWAGEN, M. E.: The pharmacology of butorphanol, a 3,14-dihydroxymorphinan narcotic antagonist analgesic. Arch. Int. Pharmacodyn. Ther. 220: 231-257, 1976.
43. PORTOGHESE, P. S., LIPKOWSKI, A. W. AND TAKEMORI, A. E.: Binaltorphimine and nor-binaltorphimine, potent and selective κ-opioid receptor antagonists. Life Sci. 40: 1287-1292, 1987.
44. RASMUSSEN, K. AND AGHAJANIAN, G. K.: Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: Attenuation by lesion of the nucleus paragigantocellularis. Brain Res. 505: 346-350, 1989.
45. RASMUSSEN, K., BEITNER-JOHNSON, D. B., KRYSTAL, J. H., AGHAJANIAN, G. K. AND NESTLER, E. J.: Opiate withdrawal and the rat locus coeruleus: Behavioral, electrophysiological, and biochemical correlates. J. Neurosci. 10: 2308-2317, 1990.
46. RASMUSSEN, K., FULLER, R. W., STOCKTON, M. E., PERRY, K. W., SWINFORD, R. M. AND ORNSTEIN, P. L.: NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur. J. Pharmacol. 197: 9-16, 1991a.
47. RASMUSSEN, K., KRYSTAL, J. H. AND AGHAJANIAN, G. K.: Excitatory amino acids and morphine withdrawal: Differential effects of central and peripheral kynurenic acid administration. Psychopharmacology 105: 508-512, 1991b.
48. REDMOND, D. E., JR. AND KRYSTAL, J. H.: Multiple mechanisms of withdrawal from opioid drugs. Annu. Rev. Neurosci. 7: 443-478, 1984.
49. SMITH, S. G. AND DAVIS, W. M.: Nonmedical use of butorphanol and diphenhydramine. JAMA 252: 1010, 1984.
50. TAKEMORI, A. E., HO, B. Y., NAESETH, J. S. AND PORTOGHESE, P. S.: Nor-binaltorphimine: A highly selective kappa opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 246: 255-258, 1988.
51. TANGANELLI, S., ANTONELLI, T., MORARI, M., BIANCHI, C. AND BEANI, L.: Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neurosci. Lett. 122: 270-272, 1991.
52. TRUJILLO, K. A. AND AKIL, H.: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251: 85-87, 1991.
53. TUNG, C.-S., GRENHOFF, J. AND SVENSSON, T. H.: Morphine withdrawal responses of rat locus coeruleus neurons are blocked by an excitatory amino acid antagonist. Acta Physiol. Scand. 138: 581-582, 1990.
54. WILKINSON, D. J.: Opioid agonist/antagonists in general anesthesia. Br. J. Hosp. Med. 38: 130-133, 1987.
55. WOODS, J. H. AND GMEREK, D. E.: Substitution and primary dependence studies in animals. Drug Alcohol Depend. 14: 233-247, 1985.
56. ZHANG, T., FENG, Y. Z., ROCKHOLD, R. W. AND HO, I. K.: Naloxone-precipitated morphine withdrawal increases pontine glutamate levels in the rat. Life Sci. 55: PL25-31, 1994.